eldelumab

Home
Ligands
eldelumab

GtoPdb Ligand ID: 9047

Synonyms: BMS-936557 | MDX-1100

Comment: Eldelumab (BMS-936557 and formerly MDX-1100) is a a fully human monoclonal antibody targeting the chemokine CXCL10 (a.k.a. interferon-γ-inducible protein-10 or IP-10) [1]. It is being investigated for its anti-inflammatory action in autoimmune conditions.
BLAST peptide sequence analysis reveals exact matches with heavy and light chain variable regions claimed in patent US8258266, and identify eldelumab as clone 6A5 [1].

References
1. Deshpande S, Huang H, Srinivasan M, Cardarelli JM, Wang C, Passmore DB, Rangan V, Lane TE, Keirstead HS, Liu MT. (2012) IP-10 antibodies and their uses. Patent number: US8258266 B2. Assignee: Medarex, Inc.. Priority date: 10/12/2003. Publication date: 04/09/2012.
2. Mayer L, Sandborn WJ, Stepanov Y, Geboes K, Hardi R, Yellin M, Tao X, Xu LA, Salter-Cid L, Gujrathi S et al.. (2014) Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut, 63 (3): 442-50. [PMID:23461895]
3. Yellin M, Paliienko I, Balanescu A, Ter-Vartanian S, Tseluyko V, Xu LA, Tao X, Cardarelli PM, Leblanc H, Nichol G et al.. (2012) A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum, 64 (6): 1730-9. [PMID:22147649]

References

1. Deshpande S, Huang H, Srinivasan M, Cardarelli JM, Wang C, Passmore DB, Rangan V, Lane TE, Keirstead HS, Liu MT. (2012)
IP-10 antibodies and their uses.
Patent number: US8258266 B2. Assignee: Medarex, Inc.. Priority date: 10/12/2003. Publication date: 04/09/2012.

2. Mayer L, Sandborn WJ, Stepanov Y, Geboes K, Hardi R, Yellin M, Tao X, Xu LA, Salter-Cid L, Gujrathi S et al.. (2014)
Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study.
Gut, 63 (3): 442-50. [PMID:23461895]

3. Yellin M, Paliienko I, Balanescu A, Ter-Vartanian S, Tseluyko V, Xu LA, Tao X, Cardarelli PM, Leblanc H, Nichol G et al.. (2012)
A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis.
Arthritis Rheum, 64 (6): 1730-9. [PMID:22147649]